Connection

Alessandro Rambaldi to Myeloproliferative Disorders

Back to Details
This is a "connection" page, showing publications Alessandro Rambaldi has written about Myeloproliferative Disorders.
Alessandro Rambaldi
Connection Strength
2.482
Myeloproliferative Disorders
  1. Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 06 16; 11(6):115.
    View in: PubMed
    Score: 0.630
  2. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 02; 35(2):485-493.
    View in: PubMed
    Score: 0.612
  3. Inflammation and myeloproliferative neoplasms. J Autoimmun. 2017 Dec; 85:58-63.
    View in: PubMed
    Score: 0.479
  4. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue. Expert Rev Hematol. 2013 Aug; 6(4):429-39.
    View in: PubMed
    Score: 0.365
  5. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 02 04; 11(2):21.
    View in: PubMed
    Score: 0.154
  6. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 05; 32(5):1200-1210.
    View in: PubMed
    Score: 0.125
  7. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017 02 22; 10(1):54.
    View in: PubMed
    Score: 0.117
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.